This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gray, O. Articles by Hawkins, S. Search for Related Content PubMed PubMed Citation Articles by Gray, O. Articles by Hawkins, S. Pubmed/NCBI databases UniSTS Social Bookmarking                         What's this?

An investigation of susceptibility loci in benign, aggressive and primary progressive multiple sclerosis in Northern Irish population

Department of Neurology, Royal Victoria Hospital, Grosvenor Road, Belfast, N. Ireland. BT12 6BA orlagray{at}hotmail.com

H Abdeen

Genetics Laboratories, Belfast Health and Social Care Trust, Lisburn Road, Belfast, N. Ireland. BT9 7AB

GV McDonnell

Department of Neurology, Royal Victoria Hospital, Grosvenor Road, Belfast, N. Ireland. BT12 6BA

CC Patterson

Epidemiology Research Group, Mulhouse Building, Queen’s University, Grosvenor Road, Belfast, N. Ireland. BT12 6BJ

CA Graham

Genetics Laboratories, Belfast Health and Social Care Trust, Lisburn Road, Belfast, N. Ireland. BT9 7AB

SA Hawkins

Division of Medicine and Therapeutics, Queen’s University, Grosvenor Road, Belfast, N. Ireland. BT12 6BJ

Objective

To investigate the possibility that susceptibility loci in multiple sclerosis (MS) have a role in determining the disease outcome in Northern Ireland population.

Background

The Genetic Analysis of Multiple Sclerosis in Europeans (GAMES) initiative and follow-up refined analysis identified 15 candidate susceptibility loci within the Northern Irish population for MS. We aimed to investigate the 12 most significant markers for their role in disease outcome.

Methods

Cases with probable or definite MS (Poser criteria) were classified as benign onset (Kurtzke Expanded Disability Status Scale [EDSS]  3.0 at 10 years), aggressive (Kurtzke EDSS  6.0 by 10 years), or primary progressive MS. All cases were Caucasian of Northern Irish origin. DNA was extracted from venous blood, microsatellite markers were amplified using polymerase chain reaction and typed using fluorescent fragment analysis. Allele frequencies were compared statistically using a chi-squared test with allowance for multiple comparisons (critical P < 0.0042); significant markers were further analyzed by CLUMP (critical P < 0.0014).

Results

Two microsatellite markers were significant: D3S1278 (Chr 3q13, P < 0.001) and tumor necrosis factor (TNF)- (Chr 6p21, P < 0.001). A further three markers were significant in our preliminary analysis suggesting a trend toward impact on disease outcome; D4S432 (Chr 4p16, P = 0.001), D2S347 (Chr 2q14, P = 0.003), and D19S903 (Chr 19p13, P = 0.003).

Conclusions

This is the first study to suggest a role for TNF- in the disease outcome in MS. Larger replication studies need to be performed to assess the role of markers D4S432, D2S347, and D19S903.

Key Words: genetics • multiple sclerosis • Northern Ireland • susceptibility genes

Multiple Sclerosis, Vol. 15, No. 3, 299-303 (2009)
DOI: 10.1177/1352458508099611


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?